# FARXIGA

NDC: 55154-6933
Generic name: DAPAGLIFLOZIN
Labeler / Manufacturer: Cardinal Health 107, LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET, FILM COATED
Routes: ORAL
Marketing started: 20080114
Marketing ended: 20260731
FDA application: NDA202293

## Active ingredients

- DAPAGLIFLOZIN PROPANEDIOL: 10 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"55154-6933"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=55154-6933
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40cc4f5d-bcf6-4016-9d1e-838bbc4bdddc